NCT00092040已完成3 期
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 936
- 主要终点
- Mean percent change from baseline in hip trochanter bone mineral density (BMD)
研究概览
简要总结
The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women with osteoporosis
排除标准
- •Any known allergy to the study drug
结局指标
主要结局
Mean percent change from baseline in hip trochanter bone mineral density (BMD)
次要结局
- Mean percent change from baseline in PA lumbar spine, total hip, and femoral neck BMD
研究者
相似试验
已完成
2 期
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive PatientsHypertensionNCT00939588Novartis Pharmaceuticals88
已完成
4 期
A Study Evaluating Duloxetine in Patients Hospitalized for Severe DepressionMajor Depressive DisorderNCT00422162Eli Lilly and Company339
已完成
3 期
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)Exercise Induced AsthmaNCT00127166Organon and Co154
已完成
4 期
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment WithdrawalHypertensionNCT00865020Novartis822
Unknown
3 期
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 YearsAsthmaNCT03387241Mundipharma (China) Pharmaceutical Co. Ltd330